Brief: Artelo Announces Third-Party Fully Funded Clinical Study Agreement To Evaluate Art27.13 In Glaucoma Patients
18/03/2026 12:01
March 18 (Reuters) - Artelo Biosciences Inc ARTL.O: ARTELO ANNOUNCES THIRD-PARTY FULLY FUNDED CLINICAL STUDY AGREEMENT TO EVALUATE ART27.13 IN GLAUCOMA PATIENTS ARTELO BIOSCIENCES INC - FIRST PATIENT ENROLLMENT ANTICIPATED IN Q2 2026 ARTELO BIOSCIENCES INC - TO SUPPLY ART27.13 CAPSULES AS INVESTIGATIONAL MEDICINAL PRODUCT Source text: ID:nGNX2nwSwP Further company coverage: ARTL.O ((Reuters.Briefs@thomsonreuters.com;))